SLXN
Silexion Therapeutics CorpCompany Information
- Company Name
- Silexion Therapeutics Corp
- CIK
- CIK0002022416
- Category
- <br>Emerging growth company
- Ticker: Exchange
- SLXN: Nasdaq, SLXNW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- SLXN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-03-26
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 22,818
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,761
- Shares outstanding
- 687,353
- Ownership
- 0.26%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -16.19%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 2 | 6 | 9 | 3 | 6 | 1 | 2 | 2 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | 0 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense Current | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 4 | 4 | 7 | 11 | 5 | 8 | 2 | 3 | 2 | ||||||
Assets Noncurrent | |||||||||||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | ||||||
| Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
Liabilities And Redeemable Convertible Preferred Shares Net Of Capital Deficiency | |||||||||||||||
| Assets | 4 | 5 | 7 | 12 | 6 | 8 | 3 | 3 | 2 | ||||||
Liabilities Current | |||||||||||||||
| Accounts Payable Trade Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Employee Related Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Other Accounts Payable And Accrued Liabilities | - | - | 1 | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Accounts Payable Other Current | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 4 | 4 | 3 | 3 | 2 | 2 | 4 | 4 | 2 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | |||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | 0 | 0 | 2 | 2 | 4 | 3 | 3 | 4 | 0 | ||||||
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | |||||||||||||||
| Liabilities | 4 | 4 | 5 | 5 | 6 | 6 | 7 | 8 | 2 | ||||||
Stockholders Equity | |||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 61 | 58 | 58 | 58 | 48 | 48 | 39 | 37 | 11 | ||||||
| Retained Earnings Accumulated Deficit | -61 | -58 | -55 | -51 | -47 | -45 | -43 | -42 | -30 | ||||||
| Stockholders Equity | 0 | 0 | 3 | 7 | 0 | 3 | -4 | -5 | -18 | ||||||
| Liabilities And Stockholders Equity | 4 | 5 | 7 | 12 | 6 | 8 | 3 | 3 | 3 | ||||||
| Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value | - | - | - | - | - | - | 0 | 0 | 15 | ||||||
| Related Party | -1 | 2 | 2 | -2 | 3 | 0 | 0 | -0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | 0.01 | ||||||
| Redeemable Noncontrolling Interest Equity Preferred Carrying Amount | - | - | - | - | - | - | 0 | 0 | 3 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.14 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | ||||||
| Preferred Stock Redemption Amount | - | - | - | - | - | - | 0 | 0 | 18 | ||||||
| Common Stock Shares Authorized | 6 | 9 | 9 | 9 | 1 | 22 | 1,481 | 200 | 3 | ||||||
| Common Stock Shares Issued | 1 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | ||||||
| Shares Outstanding | 1 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | ||||||
| Convertible Series A Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Convertible Series A One Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Convertible Series A Two Preferred Shares | - | - | - | - | - | - | - | - | 0 | ||||||
Assets | |||||||||||||||
| Convertible Series A2 Preferred Shares | - | - | - | - | - | - | 0 | 0 | - | ||||||
| Convertible Series A Three Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Convertible Series A Four Preferred Shares | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSilexion Therapeutics Corp (SLXN) — SEC Financial Statements & Analysis
Silexion Therapeutics Corp (SLXN) is a biological products, (no diagnostic substances) company, incorporated in E9. Silexion Therapeutics Corp trades on Nasdaq as: SLXN, SLXNW. Silexion Therapeutics Corp (SLXN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Silexion Therapeutics Corp carries a market cap of $1.75M, a P/E ratio of 0.13x, a P/B ratio of 39.84x, an enterprise value of $-567.25K, and an EV/EBITDA multiple of -0.04x. On profitability, it posts a Return on Equity (ROE) of 17021.95% and a Return on Assets (ROA) of 277.96%. Per share, it reports EPS of $20.31, diluted EPS of $20.31, free cash flow per share of $-18.09, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -276.19% year-over-year and EPS growth of -114.86% year-over-year. On the balance sheet, it maintains a current ratio of 0.94x, a quick ratio of 0.60x, working capital of $-235.00K, a debt-to-equity ratio of 95.50x, a debt ratio of 0.99, free cash flow of $-12.43M (TTM), and net debt of $-2.32M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.75M
- P/E TTM
- 0.13x
- EPS TTM
- $20.31
- P/B TTM
- 39.84x
- ROE TTM
- 17021.95%
- ROA TTM
- 277.96%
- Debt To Equity
- 95.50x
- Free Cash Flow TTM
- $-12.43M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Silexion Therapeutics Corp in?
Silexion Therapeutics Corp (SLXN) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does SLXN trade on?
Silexion Therapeutics Corp (SLXN) trades on the Nasdaq.
Where is Silexion Therapeutics Corp incorporated?
Silexion Therapeutics Corp is incorporated in Cayman Islands.
When was Silexion Therapeutics Corp (SLXN)'s most recent SEC filing?
Silexion Therapeutics Corp (SLXN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is SLXN's market cap?
Silexion Therapeutics Corp (SLXN) has a market capitalization of $1.75M as of 2026-06-30.
What is SLXN's P/E ratio?
Silexion Therapeutics Corp (SLXN)'s trailing twelve month P/E ratio is 0.13x as of 2026-06-30.
What is SLXN's EPS (earnings per share)?
Silexion Therapeutics Corp (SLXN)'s trailing twelve month EPS is $20.31 as of 2026-06-30.
What is SLXN's ROE (return on equity)?
Silexion Therapeutics Corp (SLXN)'s trailing twelve month Return on Equity (ROE) is 17021.95% as of 2026-06-30.
What is SLXN's ROA (return on assets)?
Silexion Therapeutics Corp (SLXN)'s trailing twelve month Return on Assets (ROA) is 277.96% as of 2026-06-30.
What is SLXN's EV/EBITDA?
Silexion Therapeutics Corp (SLXN)'s trailing twelve month EV/EBITDA is -0.04x as of 2026-06-30.